4527 — Rohto Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for Rohto Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2019 March 31st	2020 March 31st	2021 March 31st	R2022 March 31st	2023 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	JAS	JAS	JAS	JAS	JAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	183,582	188,327	181,287	199,646	238,664
Cost of Revenue
Gross Profit	109,534	114,192	106,961	116,170	137,421
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	165,439	168,372	161,937	171,583	205,999
Operating Profit	18,143	19,955	19,350	28,063	32,665
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	16,300	21,730	23,006	27,874	34,290
Provision for Income Taxes
Net Income After Taxes	9,819	15,282	16,770	21,188	26,430
Minority Interest
Net Income Before Extraordinary Items
Net Income	9,801	15,409	16,743	21,128	26,378
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	9,799	15,410	16,743	21,127	26,377
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	50.9	78.7	77.8	97.5	121
Dividends per Share
Special Dividends per Share